Catherine Friedman - Theseus Pharmaceuticals Independent Director
| THRXDelisted Stock | USD 4.06 0.00 0.00% |
Director
Catherine J. Friedman is Directors of the Company since June 2014. Ms. Friedman has served as an independent consultant serving public and private growth companies since 2006. Prior to that Ms. Friedman held the position of Managing Director at Morgan Stanley from 1997 to 2006 and Head of West Coast Healthcare and CoHead of the Biotechnology Practice at Morgan Stanley from 1993 to 2006. Ms. Friedman has served on the Board of Directors of GSV Capital Corporationration since 2013. She is also on the Board of Directors of XenoPort Inc. a publicly traded biopharmaceutical company and Enteromedics a publicly traded medical device company since 2007. Ms. Friedman is a member of the Board of Trustees for Sacred Heart Schools in Atherton California and she serves as a Trustee for the Darden School Foundation at the University of Virginia. She has a B.A. from Harvard University and received an M.B.A. from the University of Virginia Darden Graduate School of Business. Ms. Friedman demonstrated leadership in her field her knowledge of financial and financing matters and her prior board service contributed to our conclusion that she should serve as a director. since 2014.
| Age | 54 |
| Tenure | 10 years |
| Phone | 857 400 9491 |
| Web | https://theseusrx.com |
Theseus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1789) % which means that it has lost $0.1789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2555) %, meaning that it created substantial loss on money invested by shareholders. Theseus Pharmaceuticals' management efficiency ratios could be used to measure how well Theseus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 3.98 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Theseus Pharmaceuticals has a current ratio of 26.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Theseus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Theseus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Theseus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Theseus to invest in growth at high rates of return. When we think about Theseus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Rene Russo | X4 Pharmaceuticals | 42 | |
| Yasunori Kaneko | Arcus Biosciences | 66 | |
| Nicholas Lydon | Blueprint Medicines Corp | 61 | |
| Jeffrey Hatfield | aTyr Pharma | 59 | |
| Stephen Knight | Blueprint Medicines Corp | 55 | |
| Timothy Coughlin | aTyr Pharma | 51 | |
| Patrick Machado | Arcus Biosciences | 55 | |
| David Beier | Arcus Biosciences | 69 | |
| Kathryn Falberg | aTyr Pharma | 54 | |
| Isaac Blech | X4 Pharmaceuticals | N/A | |
| Kristen Hege | Mersana Therapeutics | 54 | |
| Sarah Payne | Terns Pharmaceuticals | 41 | |
| Paul Schimmel | aTyr Pharma | 77 | |
| Lawrence Alleva | Mersana Therapeutics | 67 | |
| Michael Landsittel | Blueprint Medicines Corp | 52 | |
| Willard Dere | Mersana Therapeutics | 64 | |
| James Blair | aTyr Pharma | 78 | |
| Angus Forrest | Terns Pharmaceuticals | N/A | |
| Kathryn Falberg | Arcus Biosciences | 60 | |
| Lynn Seely | Blueprint Medicines Corp | 59 | |
| Svetlana Lucas | aTyr Pharma | N/A | |
Management Performance
| Return On Equity | -0.26 | |||
| Return On Asset | -0.18 |
Theseus Pharmaceuticals Leadership Team
Elected by the shareholders, the Theseus Pharmaceuticals' board of directors comprises two types of representatives: Theseus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theseus. The board's role is to monitor Theseus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Theseus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theseus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick LePore, Independent Director | ||
| DPhil DPHIL, CoFounder Chairman | ||
| Nachu Narasimhan, VP Safety | ||
| Theodore Witek, Sr. VP of Corporate Partnerships, Clinical and Medical Affairs | ||
| WeiSheng Huang, CoFounder Chemistry | ||
| Catherine Friedman, Independent Director | ||
| James Tyree, Independent Director | ||
| Terrence Kearney, Independent Director | ||
| Michael Faerm, Chief Bus. Officer and Sr. VP | ||
| Barbara Duncan, Independent Director | ||
| Paul Pepe, Independent Director | ||
| George Abercrombie, Senior Vice President - Corporate Partnerships, Commercial | ||
| Timothy Clackson, Pres CEO | ||
| Len Rozamus, VP Operations | ||
| Eric dEsparbes, CFO and Sr. VP | ||
| Bradford Dahms, Chief officer | ||
| Alicja Januszewicz, VP Culture | ||
| Victor Rivera, VP CoFounder | ||
| Benjamin Enerson, VP Affairs | ||
| Michael Aguiar, CEO and President and Director | ||
| Kristine CPA, VP Controller | ||
| William Waltrip, Lead Independent Director | ||
| MA DPHIL, CoFounder Chairman | ||
| David MD, Chief Officer | ||
| William Shakespeare, CoFounder RD |
Theseus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theseus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | (20.19 M) | |||
| Shares Outstanding | 44.65 M | |||
| Shares Owned By Insiders | 2.55 % | |||
| Shares Owned By Institutions | 93.28 % | |||
| Number Of Shares Shorted | 401.68 K | |||
| Price To Earning | 737.67 X | |||
| Price To Book | 0.81 X | |||
| EBITDA | (66.44 M) |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Theseus Stock
If you are still planning to invest in Theseus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Theseus Pharmaceuticals' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |